Project 2021

About Project 2021

For further information, see theProject Twenty21 Australia is a collaboration between the ACCM and Drug Science Org in the UK. Project Twenty21 is already underway in the UK (https://www.drugscience.org.uk/).  Project Twenty21 Australia is the Australian arm of this project, where data will be collected in an Australian population in four of the eight clinical conditions being investigated in the UK. These clinical conditions will be:

– chronic pain

– anxiety

– post-traumatic stress disorder (PTSD)

– multiple sclerosis (MS)

Project Twenty21 Australia is an open-label, prospective observational cohort study. It will follow patients prescribed medicinal cannabis in Releaf Clinics for the above-mentioned conditions for up to 6 months, collecting data on efficacy, safety and tolerability. The study will collect ‘real world data’ since it is measuring outcome variables over an extended time-period and the medicinal cannabis products will be individualised to the participants. Medicinal cannabis products prescribed to study participants are chosen from a select range of products and will be available at a discounted price to study participants for the duration of their participation in the study. The study began in January 2022 and will continue recruitment until the end of May 2023. Visit drugscience.org.uk  for information on the UK study.

For further information, see the Participant Information form. To register your interest you can contact the Study Coordinator Ms Michelle Frans (registered nurse) on 03 9988 0878 or via email: michelle@releafgroupltd.com or register your interest by filling in your details below:

Register your interest in participating